
Elicera Therapeutics Q3 - CARMA study on the way

Redeye returns following Elicera's Q3 report and recent news in the company. We largely reiterate our stance and see an exciting news flow ahead, most notably related to the ongoing studies with ELC-301 and ELC-100.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Elicera Therapeutics Q3 - CARMA study on the way](#)